Spots Global Cancer Trial Database for Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Oxaliplatin and Cetuximab in First-line Treatment of Metastatic Colorectal Cancer (mCRC)
Official Title: Open, Randomized, Controlled, Multicenter Phase II Study Comparing 5-FU/FA Plus Oxaliplatin (FOLFOX-4) Plus Cetuximab Versus 5-FU/FA Plus Oxaliplatin (FOLFOX-4) as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer
Study ID: NCT00125034
Study Description
Brief Summary: This is an open label, randomized, controlled, multicenter phase II study comparing 5-FU/FA + oxaliplatin (FOLFOX-4) + cetuximab versus 5-FU/FA + oxaliplatin as first-line treatment for epidermal growth factor receptor (EGFR)-expressing mCRC.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Graz, , Austria
Research Site, Linz, , Austria
Research Site, Salzburg, , Austria
Research Site, Wien, , Austria
Research Site, Zams, , Austria
Research Site, Antwerpen, , Belgium
Research Site, Bonheiden, , Belgium
Research Site, Brugge, , Belgium
Research Site, Hasselt, , Belgium
Research Site, Leuven, , Belgium
Research Site, Roeselare, , Belgium
Research Site, Turnhout, , Belgium
Research Site, ZU Gent, , Belgium
Research Site, Besancon, , France
Research Site, Clermond Ferrand, , France
Research Site, Clichy, , France
Research Site, Montpellier, , France
Research Site, Paris, , France
Research Site, Rouen, , France
Research Site, Strasbourg, , France
Research Site, Aschaffenburg, , Germany
Research Site, Dresden, , Germany
Research Site, Essen, , Germany
Research Site, Hamburg, , Germany
Research Site, Kiel, , Germany
Research Site, Magdeburg, , Germany
Research Site, Mannheim, , Germany
Research Site, Nürnberg, , Germany
Research Site, Tübingen, , Germany
Research Site, Athens, , Greece
Research Site, Loannina, , Greece
Research Site, Thessaloniki, , Greece
Research Site, Haifa, , Israel
Research Site, Kfar-Saba, , Israel
Research Site, Petah Tiqva, , Israel
Research Site, Rehovot, , Israel
Research Site, Tel-Aviv, , Israel
Research Site, Tel-Hashomer, , Israel
Research Site, Brescia, , Italy
Research Site, Milano, , Italy
Research Site, Padova, , Italy
Research Site, Pavia, , Italy
Research Site, Rome, , Italy
Research Site, Torino, , Italy
Research Site, Bialystok, , Poland
Research Site, Krakow, , Poland
Research Site, Lublin, , Poland
Research Site, Opole, , Poland
Research Site, Poznan, , Poland
Research Site, Szczecin, , Poland
Research Site, Warszawa, , Poland
Research Site, Lisbon, , Portugal
Research Site, Santa Maira da Feira, , Portugal
Research Site, Alba Iulia, , Romania
Research Site, Bucurest, , Romania
Research Site, Onesti, , Romania
Research Site, Oradea, , Romania
Research Site, Timisoara, , Romania
Research Site, Kazan, , Russian Federation
Research Site, Krasnodar, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Obninsk, , Russian Federation
Research Site, Samara, , Russian Federation
Research Site, St. Petersburg, , Russian Federation
Research Site, Bilbao, , Spain
Research Site, Burgos, , Spain
Research Site, Girona, , Spain
Research Site, Madrid, , Spain
Research Site, Malaga, , Spain
Research Site, Orense, , Spain
Research Site, Reus, , Spain
Research Site, Valencia, , Spain
Research Site, Dnepropetrovsk, , Ukraine
Research Site, Kharkov, , Ukraine
Research Site, Kiev, , Ukraine
Research Site, Lviv, , Ukraine
Research Site, Simferopol, , Ukraine
Research Site, Vinnitsa, , Ukraine
Contact Details
Name: Bokemeyer, Prof. Dr.
Affiliation: Klinik für Onkologie, Hämatologie und Knochenmarktransplantationen Universitätsklinikum Hamburg-Eppendorf, Germany
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
